<DOC>
	<DOCNO>NCT00003567</DOCNO>
	<brief_summary>RATIONALE : Gene therapy may improve body 's ability fight cancer make cancer sensitive chemotherapy . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . PURPOSE : This phase I trial study side effect best dose gene therapy together chemotherapy treat patient advance solid tumor non-Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Gene Therapy Chemotherapy Treating Patients With Advanced Solid Tumors Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Evaluate feasibility introduce express mutant MGMT-G156A cDNA hematopoietic progenitor take patient advance solid tumor ( include glioma ) non-Hodgkin 's lymphoma use safety modify retroviral vector MFG . - Determine toxicity associate reinfusion ex vivo-transduced hematopoietic stem cell patient , include detection replication competent retrovirus . - Evaluate feasibility identify mutant MGMT-G156A-transduced O6-benzylguanine ( BG ) - temzolomide-resistant hematopoietic stromal progenitor bone marrow patient . - Evaluate feasibility vivo enrichment transduce hematopoietic progenitor patient treat BG temzolomide . - Evaluate toxicity regimen patient . - Determine antitumor effect regimen patient . OUTLINE : This dose-escalation study CD34 stem cell carmustine . After negative bone marrow sampling , patient receive sargramostim ( GM-CSF ) filgrastim ( G-CSF ) subcutaneously ( SC ) daily day 1-5 ( G-CSF twice daily alone 4-5 day ) . Peripheral blood progenitor cell collect 24 hour last dose growth factor injection day 5 also day 6 , necessary . The CD34 positive stem cell infected retroviral mutant MGMT-G156A ex vivo . Patients receive O6-benzylguanine ( BG ) IV 1 hour follow carmustine IV 1 hour every 6 week 5 course , assume recovery peripheral blood count . Approximately 72 hour end first course chemotherapy , patient receive reinfusion retrovirally-transduced hematopoietic stem cell 5-10 minute . Four week completion BG carmustine , patient receive BG IV 1 hour follow temozolomide IV 1 hour every 4 week 5 course , absence hematologic toxicity . Patients respond disease may continue receive BG temzolomide absence disease progression unacceptable toxicity provide phase II study indicate safety 5 course . Cohorts 3-6 patient receive escalate number CD34 stem cell target retroviral infection escalate dos carmustine . Patients follow monthly 2 month , every 4 month 8 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 12-18 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<mesh_term>O ( 6 ) -benzylguanine</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow histologically confirm disease curative surgical , radiotherapy , chemotherapy program available standard therapy offer , best , modest clinical benefit Solid tumor Gliomas NonHodgkin 's lymphoma Primary metastatic CNS malignancy eligible Evaluable measurable disease CD34 count least 2.0 cells/Î¼L No bone marrow involvement Histologically negative bone marrow biopsy PATIENT CHARACTERISTICS : Age : 18 70 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hemoglobin least 8.5 g/dL Hepatic : Bilirubin great 1.5 mg/dL AST ALT less 2.5 time normal Prothrombin time le 1.2 time normal Renal : Creatinine great 2.0 mg/dL Cardiovascular : No acute cardiac disease EKG Pulmonary : No symptomatic pulmonary disease Other : HIV negative No severe comorbid condition Not pregnant nursing Fertile patient must use effective contraception 2 month study completion PRIOR CONCURRENT THERAPY : Biologic therapy : See Chemotherapy No prior hematopoietic stem cell transplantation Chemotherapy : No prior highdose chemotherapy Prior adjuvant chemotherapy allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy 25 % bone marrow Surgery : Not specify Other : At least 4 week since prior myelosuppressive therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>recurrent adult brain tumor</keyword>
	<keyword>adult brain stem glioma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>adult mixed glioma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>adult anaplastic astrocytoma</keyword>
	<keyword>adult anaplastic oligodendroglioma</keyword>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult pilocytic astrocytoma</keyword>
	<keyword>adult subependymoma</keyword>
	<keyword>adult anaplastic ependymoma</keyword>
	<keyword>adult myxopapillary ependymoma</keyword>
	<keyword>adult ependymoblastoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult oligodendroglioma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
	<keyword>adult diffuse astrocytoma</keyword>
</DOC>